About Halozyme
Halozyme is a publicly listed company based in San Diego (United States) founded in 1999. Drug delivery technologies for disease treatment are developed. The company has 350 employees. Halozyme has completed 3 acquisitions, including Antares Pharma, Elektrofi and Surf Bio. Its chief executive, as recorded, is Helen Torley. Its website halozyme.com draws about 12 thousand monthly visits. Halozyme offers products and services including ENHANZE, Auto-Injector, and Multi-Dose Pen Technologies. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Halozyme, Inc. Its competitors include Insulet, C4 Therapeutics and Erasca; 3 of its 3 listed competitors have raised funding.
Company details
Halozyme was founded in 1999 and is headquartered in San Diego, United States. Operations focus on the biotechnology sector, where drug delivery technologies are developed to address various diseases. The lead product, ENHANZE, utilizes the proprietary enzyme rHuPH20 to enhance the delivery of injected drugs and fluids. Additionally, Hylenex, a recombinant endoglycosidase, is offered as an adjuvant to improve the dispersion and absorption of other injected drugs.
- Headquarters San Diego, United States
- Employees 350
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website halozyme.com
- Social LinkedIn X
- Legal Name Halozyme Therapeutics, Inc.
- Annual Revenue$1.4 B (USD)37.55as on Dec 31, 2025
- Net Profit$316.89 M (USD)-28.64as on Dec 31, 2025
- EBITDA$904.34 M (USD)42.91as on Dec 31, 2025
- Latest Funding Round$625M (USD), Post-IPO
Aug 2022
- InvestorsSVB
& 4 more
- Employee Count350
- Investments & AcquisitionsAntares Pharma
& 2 more
Products & Services of Halozyme
Halozyme offers a comprehensive portfolio of products and services, including ENHANZE, Auto-Injector, and Multi-Dose Pen Technologies.
Enhances drug administration for better patient treatment efficacy.
Provides automatic injection solutions for simplified medication delivery.
Offers multi-dose systems to improve drug dosing accuracy and convenience.
Funding Insights of Halozyme
- Total Rounds 8
- Last Round Post-IPO — $625M
- First Round $11M
(Dec 2006)
- Investors Count 5
All 8 funding rounds of Halozyme with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $625M | Post-IPO | – | – | – |
| Nov 2019 | $388.5M | Post-IPO | – | – | – |
| Jan 2016 | $150M | Debt – Venture | – | – | |
| Jan 2014 | $20M | Debt – Venture | – | – | |
| Dec 2012 | $30M | Debt – Venture | – | – | |
| Nov 2010 | $977,917 | Grant | – | – | – |
| May 2007 | $32.1M | Post-IPO | – | – | – |
| Dec 2006 | $11M | Post-IPO | – | – |
5 investors in total: 5 institutional.
Investors in Halozyme
Halozyme has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Oxford Finance and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Corporate-backed venture capital firm focused on the healthcare sector | roche.com/venturefund.htm | |||
| biopharmafunds.com | ||||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States |
Investor details for Halozyme
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Halozyme
138 people are tracked at Halozyme (70 in leadership, 68 in team); the tracked headcount is 350.
| Name | Role | Group |
|---|---|---|
Helen Torley | CEO & President | Leadership |
Dimitrios Chondros | Senior Vice President, Chief Medical Officer | Leadership |
Benjamin J. Hickey | Senior Vice President, Chief Commercial Officer | Leadership |
Michael E. Paolucci | Vice President and Chief Human Resources Officer | Leadership |
Anna-Maria Hays Putnam | Vice President, Development And Manufacturing | Leadership |
Bryan Zart | Director Finished Product Manufacturing Operations | Leadership |
Tyler Krol | Senior Director Quality | Leadership |
Emanuel Leon | Director, Drug Product Operations | Leadership |
David Kang | Associate Director Drug Delivery | Leadership |
Charles Theuer | Chief Medical Officer | Leadership |
Kristin Schwartzbauer | Vp, Quality | Head Of Quality | Leadership |
Kodjo Adadevoh | Senior Director, Quality Technical Operations | Leadership |
Dan Vogel | Sr. Director, Access Pull Through & Commercial Growth Initiatives | Leadership |
Cliff J. | Senior Director, Information Technology | Leadership |
Jeffrey Erickson | Vice President, Business Development | Leadership |
Ed Gemo | Vice President, Chief Information & Security Officer | Leadership |
Sahiba Kaur | Associate Director | Leadership |
Amber Hemberger | Director, Biopharma Quality Assurance | Leadership |
Amir Nakash | Vice President | Leadership |
Chris Fan | Director, Fp&a | Leadership |
118 more people are available in the full profile.
Complete people profiles for Halozyme
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Halozyme
Halozyme is a publicly listed company on the NASDAQ with ticker symbol HALO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Mar 2004
- Listed onNASDAQ: HALO
- Listed entityHalozyme Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS40637H1095
- Share price$109.62 (-1.31% on the day) · 2026-10-13
- Market capitalisation$12.44B
- Price to earnings32.8
- EPS (diluted, trailing year)$3.35
- Volume (last session)1,772,731
Financials of Halozyme
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.40B | $316.9M | $904.3M |
| 2024 | $1.02B | $444.1M | $632.8M |
| 2023 | $829.2M | $281.6M | $422.4M |
| 2022 | $660.1M | $202.1M | $339.1M |
| 2021 | $443.3M | $402.7M | $278.9M |
Detailed financial statements for Halozyme
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Halozyme
Halozyme has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Antares Pharma, Elektrofi and Surf Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for diabetes and other diseases are developed via biotechnology. | surf.bio | Palo Alto, United States | 2021 | Jan 2026 | $300M | |
Digital platform transforming the delivery of biologic medicines | elektrofi.com | Boston, United States | 2016 | Oct 2025 | •••• | |
Existing drugs are reformulated using proprietary pen injectors. | antarespharma.com | Ewing, United States | 2000 | Apr 2022 | $960M |
Complete acquisition details for Halozyme
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Halozyme
7 dated milestones of Halozyme across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Halozyme is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $11.0M.
- Acquisition Acquires Antares Pharma.
- Funding Latest funding round, Post-IPO, of $625.0M.
- Acquisition Acquires Elektrofi.
- Acquisition Acquires Surf Bio.
Competitors of Halozyme
Halozyme has 3 listed competitors in our database, 3 of them funded. They include Insulet, C4 Therapeutics and Erasca.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insulet.com | 2000 | Boston, United States | $120.4M | 2,600 | Wearable insulin infusion systems are developed for diabetes patients. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. |
Detailed competitors of Halozyme
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Halozyme
The website of Halozyme (halozyme.com) receives about 11.6K visits a month and ranks #1,481,510 among all websites worldwide, #1,944 in Biotechnology and Pharmaceuticals.
- Monthly visits11.6K
▼ 20.2% vs previous month
- Unique visitors6.9K
per month
- Global rank#1,481,510
among all websites
- Category rank#1,944
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit2.5
- Average visit37 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with Halozyme. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
nanobio.com | nanobio.com | 100% | – | ||
| arenapharm.com | 96% | View details | |||
| concertpharma.com | 96% | View details | |||
| keryx.com | 96% | View details | |||
alxn.com | alxn.com | 96% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for Halozyme
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Halozyme (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Halozyme
Complete news archive for Halozyme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Halozyme
Halozyme was founded in 1999 and raised its 1st funding round 7 years after it was founded.
Halozyme is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Helen Torley is the CEO of Halozyme, as recorded in our data.
Halozyme has 350 employees.
Annual revenue of Halozyme is $1.4B as on Dec 31, 2025.
Halozyme was founded in 1999 and is headquartered in San Diego, United States. Operations focus on the biotechnology sector, where drug delivery technologies are developed to address various diseases. The lead product, ENHANZE, utilizes the proprietary enzyme rHuPH20 to enhance the delivery of injected drugs and fluids. Additionally, Hylenex, a recombinant endoglycosidase, is offered as an adjuvant to improve the dispersion and absorption of other injected drugs.
Halozyme's top competitors include C4 Therapeutics, Insulet and Erasca.
Halozyme offers ENHANZE, Auto-Injector, and Multi-Dose Pen Technologies.
Yes, Halozyme is publicly traded on NASDAQ under the ticker symbol HALO.
Halozyme has made 3 acquisitions, including Antares Pharma, Elektrofi, and Surf Bio.
Halozyme has 5 investors. Key investors include SVB, Oxford Finance, Athyrium Capital Management, BioPharma Funds, and Roche.
Halozyme operates through Halozyme, Inc..